CDK4 and breast cancer: Accumulating studies revealed that aberrant CDK4 could participate in many cellular pathways associated with malignancies, including the PI3K/Akt signalling pathway in lung cancer, the Wnt/β‐catenin signalling pathway in BC and the JAK‐STAT signalling pathway in gastric cancer.14, 15, 16